CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine
Portfolio Pulse from Benzinga Newsdesk
CSL and Arcturus Therapeutics announced that Nature Communications has published pivotal data demonstrating the efficacy and tolerability of their self-amplifying (sa-mRNA) COVID-19 vaccine, ARCT-154. The data shows superior immunogenicity to Omicron BA 4/5 and longer duration of immunity compared to traditional mRNA COVID-19 vaccine boosters.
May 20, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics' sa-mRNA COVID-19 vaccine, ARCT-154, has shown superior immunogenicity and longer duration of immunity compared to traditional mRNA vaccines, as published in Nature Communications.
The publication of positive data in a reputable journal like Nature Communications is likely to boost investor confidence and positively impact the stock price of Arcturus Therapeutics in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
CSL's collaboration with Arcturus Therapeutics on the sa-mRNA COVID-19 vaccine, ARCT-154, has yielded positive results, showing superior immunogenicity and longer duration of immunity.
The positive data from the ARCT-154 vaccine study is likely to enhance CSL's reputation and investor sentiment, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 80